Last reviewed · How we verify
Lenalidomide, dexamethasone
Lenalidomide enhances immune cell proliferation and anti-tumor activity while dexamethasone provides anti-inflammatory and immunomodulatory effects to treat multiple myeloma.
Lenalidomide enhances immune cell proliferation and anti-tumor activity while dexamethasone provides anti-inflammatory and immunomodulatory effects to treat multiple myeloma. Used for Multiple myeloma (newly diagnosed and relapsed/refractory), Myelodysplastic syndromes with deletion 5q.
At a glance
| Generic name | Lenalidomide, dexamethasone |
|---|---|
| Also known as | Revlimid |
| Sponsor | IRCCS Centro di Riferimento Oncologico della Basilicata |
| Drug class | Immunomodulatory agent + corticosteroid |
| Target | Cereblon (CRBN); glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Lenalidomide is an immunomodulatory drug (IMiD) that binds cereblon, enhancing T-cell proliferation and NK cell activation while promoting tumor cell apoptosis. Dexamethasone, a corticosteroid, provides additional anti-inflammatory effects and enhances the anti-myeloma activity of lenalidomide. Together, this combination is a standard-of-care regimen for multiple myeloma treatment.
Approved indications
- Multiple myeloma (newly diagnosed and relapsed/refractory)
- Myelodysplastic syndromes with deletion 5q
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
- Constipation
- Neuropathy
- Infection
- Hyperglycemia
- Insomnia
- Venous thromboembolism
Key clinical trials
- Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma (PHASE3)
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (PHASE2)
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (PHASE3)
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma (PHASE3)
- A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant (PHASE3)
- A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma (PHASE3)
- A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (PHASE2, PHASE3)
- A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: